The development and hosting of this resource hub has been sponsored by GSK. This resource hub contains links to clinical resources, some of which may be promotional in nature.
An insight into the wide-ranging needs of respiratory patients, and how the Ellipta once-daily inhaler can help ensure patients get the full benefit of their medication.
Note: the Ellipta inhaler should be replaced once the dose counter reaches zero. Used Ellipta inhalers can be recycled. To find your nearest participating pharmacy visit www.completethecycle.eu
Critical errors study assesses commonly used inhalers
Fewer patients using Ellipta made critical errors compared with other commonly used inhalers, after reading the Patient Information Leaflet.1 A critical error is defined as inhaler usage likely to result in no, or minimal, medication being inhaled.2
Asthma critical errors study summary
COPD critical error study summary
Ellipta, Accuhaler and the shape of the respective inhalers are registered trademarks of the GSK group of companies. Other trademarks referred to herein are the property of their respective owners.
- Riley JH et al. Int J Chron Obstruct Pulmon Dis 2016; 11: 1873–1880.
- Van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
▼ Ellipta (umeclidinium/vilanterol) prescribing information
Incruse ▼ Ellipta (umeclinidium) prescribing information
Relvar Ellipta (fluticasone furoate/vilanterol) prescribing information
Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) prescribing information
Trademarks are owned by or licensed to the GSK group of companies.
Date of preparation: February 2019.